NEW! Histotripsy Treatment
Histotripsy is a groundbreaking new form of non-invasive cancer treatment using high-amplitude, short-pulse sound waves used to mechanically liquefy and destroy targeted cancerous tissue.
As the sound waves converge at a known focal point, the resulting high pressure causes extremely small, naturally occurring gas bubbles to expand, becoming many times larger than the surrounding cells.
By disrupting the cancer cell’s outer membrane, histotripsy exposes antigens that enable the immune system. Call 610-402-8759 option 4 or 835-210-4607 to talk to our team. For more information!
Histotripsy is a 100% non-invasive, non-thermal, and non-ionizing ablation for hepatic tumors. It was first developed at the University of Michigan in 2004 and received FDA approval in October of 2023. For the first time, MILV P.C. will be performing the procedure in early 2025.
Histotripsy is currently being used to treat cancerous liver tumors. The #HOPE4KIDNEY clinical trial is currently in progress, with a goal of eventually providing treatment options for the pancreas, prostrate, thyroid, breast, and beyond.
Histosonics, a company specializing in histotripsy, has developed the Edison Histotripsy System: a pioneering platform for image-guided sonic boom therapy. For histotripsy to be effective, lesions need to be visible via ultrasound.
Histotripsy is performed using General Anesthesia during the procedure.
Histotripsy can be beneficial to those with Diabetes, heart conditions, undergoing chemotherapy or on blood thinners. The entire procedure typically takes between just one and three hours to complete.
Most histotripsy patients are able to return home the same day and patients experience little to no pain and require minimal post-procedure recovery time.
Interested in learning more? Call 610-402-8759 and select option 4 or 835-210-4607 to talk to our team!
Interventional Radiology Office
1255 South Cedar Crest Blvd. Suite 2600
Allentown, PA 18103
- (610) 402-8759
- (610) 402-8585